Compare DexCom, Inc. (DXCM) vs Eaton Corporation plc (ETN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Eaton Corporation plc — how do they compare? DexCom, Inc. trades at $84.03 (market cap $31.86B), while Eaton Corporation plc trades at $429.28 (market cap $164.88B). The key difference: Eaton Corporation plc is far larger — about 5.2× DexCom, Inc.'s market cap, and Eaton Corporation plc pays a 1.04% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Eaton Corporation plc for 31 Days on average.
| DXCM | ETN | |
|---|---|---|
Market Cap | $31.86B | $164.88B |
Volume | 3,607,070 | 2,535,086 |
Sector | Health | Industrials |
52-Week High | $92.34 | $459.96 |
52-Week Low | $54.84 | $315.82 |
Typical Hold Time | 62 Days | 31 Days |
Enterprise Value | $31.32B | $185.51B |
Dividend Yield | — | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
Eaton Corporation (ETN) trades at $424.64, down 1.55% today, with a bearish technical signal despite strong fundamentals. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. ETN maintains robust profitability with 12.75% net income margin and 19.71% ROE, supported by strategic acquisitions in data center and aerospace markets. Recent news highlights growing investor attention and positive analyst coverage.
ETN presents a compelling growth story driven by data center demand and grid modernization, with 70% analyst buy ratings and a $502.38 consensus price target suggesting 18% upside. However, elevated valuation multiples (P/E 43.23) and bearish technical indicators warrant caution. Key risks include execution of acquisition strategy and competitive pressures in the electronics manufacturing sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Eaton Corporation plc
Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.
Read more on ETN →
